Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06551324 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
A Phase 3 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC), sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06551324 is a Phase 3 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC) that is actively recruiting participants, run by Pfizer. The registered enrollment target is 600 participants, above the 50-participant average among 3 other Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (1100% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT06551324, a Phase 3 study of Metastatic Castrate Resistant Prostate Cancer (mCRPC), is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Enzalutamide
- DRUG PF-06821497
Study Locations (20)
California
- Los Angeles Cancer Network - Anaheim
- UCSF Cancer Center Berkeley - Berkeley
- UCSF Cancer Center Burlingame - Burlingame
- Los Angeles Cancer Network - Fountain Valley
- Los Angeles Cancer Network - Glendale
- Los Angeles Cancer Network - Glendale
- Los Angeles Cancer Network - Los Angeles
- Los Angeles Cancer Network - Los Angeles
- Stanford Cancer Center - Palo Alto
- UCSF Investigational Drug Pharmacy - San Francisco
- UCSF Medical Center at Mission Bay - San Francisco
- UCSF Cancer Center San Mateo - San Mateo
Arizona
- Ironwood Cancer & Research Centers - Chandler
- Ironwood Cancer & Research Centers - Gilbert
- Ironwood Cancer & Research Centers - Glendale
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Phoenix
- Ironwood Cancer & Research Centers - Scottsdale
Alabama
- Urology Centers of Alabama - Homewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2028-10-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06551324
The ClinicalTrials.gov registry entry for NCT06551324 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 50-participant average among 3 other Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (1100% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castrate Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT06551324 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06551324 about?
NCT06551324 is a clinical study titled "A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).". Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or ...
What is the current status of trial NCT06551324?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2024-10-21. Estimated completion is 2028-10-29.
What conditions does trial NCT06551324 study?
This clinical trial studies the following conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC).
What interventions are being tested in trial NCT06551324?
The interventions under investigation include: Docetaxel (DRUG), Enzalutamide (DRUG), PF-06821497 (DRUG).
Who is sponsoring clinical trial NCT06551324?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06551324 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
TmPSMA-02 in mCRPC
RECRUITING · Phase 1
-
Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.